Reported a net loss of $3,020,300 for the fiscal year ended December 31, 2025, compared to a net loss of $1,077,997 in 2024. Revenue for 2025 was $16,721, down from $117,185 in 2024, reflecting the transition from selling CPAP machines to the new DeltaWave product. Operating expenses increased significantly to $2,771,786, driven largely by $2,269,500 in compensation expenses, including $2,160,000 in non-cash stock-based compensation. The company faces substantial doubt regarding its ability to continue as a going concern due to accumulated deficits and negative cash flows. Management successfully obtained FDA 510(k) clearance for the DeltaWave product in July 2024 and launched the product commercially in February 2026.